Regeneron and Sanofi today announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for Praluent (alirocumab). Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) that is intended for the treatment of patients with hypercholesterolemia.
from The Medical News http://ift.tt/1yY7zuO
from The Medical News http://ift.tt/1yY7zuO
No comments:
Post a Comment